Journey Medical Corp Announces New Journey with the Experts Video Featuring Nicholas Benner, DO — Journey Medical Corporation

Dr. Benner discusses tinea pedis, a skin condition affecting more than 3 million people yearly in the United States

 

SCOTTSDALE, Ariz.Dec. 25, 2020PRLog — Journey Medical Corporation (Journey Medical) today released a new Journey with the Experts video featuring Nicholas Benner, DO, a board-certified dermatologist who practices with Dermatologists of Central States (DOCS), and serves as a Clinical Associate Professor for the Ohio Health Dermatology Residency Program. Dr. Benner sits down with Journey Medical to discuss tinea pedis, including what it is, why it occurs and how those affected can seek treatment from their local dermatology practice.

Tinea pedis, also known as Athlete’s Foot, is a common fungal infection that can be contracted by walking barefoot in moist public places, like a swimming pool deck or locker room. Symptoms include a scaly rash that usually causes itching, stinging and burning. People with tinea pedis often have moist, raw skin between their toes.

To view the Journey with the Experts video featuring Dr. Benner, please visit https://vimeo.com/491877658/9be3062fe1.

About Journey with the Experts

Journey with the Experts is an educational initiative supported by Journey Medical Corporation, the medical dermatology company. The initiative is designed to educate the general public on common medical dermatology skin disorders and explain how these conditions can be treated at local dermatology practices.

About Journey Medical Corporation

Journey Medical is focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. The company currently markets five products that help treat and heal common skin conditions. The Journey Medical team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Journey Medical is located in Scottsdale, Arizona and is a partner company of Fortress Biotech, Inc. (NASDAQ:FBIO). For additional information about Journey Medical, visit https://journeymedicalcorp.com/.

About Nicholas Benner, DO

Dr. Benner is a board-certified dermatologist in Columbus, OH. He earned a Bachelor of Science in Biology from Indiana Wesleyan University in Marion, Indiana. He then earned his medical degree from Ohio University College of Osteopathic Medicine in Athens, OH. He followed that with his transitional internship at O’Bleness Hospital in Athens. He completed his dermatology residency in Columbus in the Ohio Health Dermatology Residency program, and served as Chief Resident his final year. Dr. Benner’s research has appeared in numerous publications including the Journal of Clinical and Aesthetic Dermatology and the Journal of the American Osteopathic College of Dermatology. For additional information about Dr. Benner, please visit https://docsdermgroup.com/listing/nicholas-a-benner-do/.

Forward Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Fortress individually, a partner company individually, or Fortress together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law.

LEAVE A REPLY

Please enter your comment!
Please enter your name here